The risk of being forced to cover by a sudden rise is balanced by the overwhelming majority of shareholders being prepared to sit and wait for the acceleration that will appear in a few years time and finally no one has a clue what Trump will do in tis area i.e. FDA and its approval process.
All IMO and DYOR of course.